Why Bionano Genomics Stock Is Tumbling Today

311
95
Favorite

Why Bionano Genomics Stock Is Tumbling Today

Motley Fool2021-04-16

What happened Shares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

311

Report

Comment（95）

Plutosg
·2021-04-25
I was worried for a while when the stock avalanched the last week.
Reply
Like
Report
VikiSoh
·2021-04-20
Bionano is best left to aggressive investors. And for these investors, Bionano is a great stock to buy in April.
Reply
Like
Report
ziqii
·2021-04-20
shag sia
Reply
1
Report
Fold Replies
- ziqii:
  hais
  2021-07-10
  Reply
  Report
Nebhol
·2021-04-19
Comment and like please
Reply
1
Report
Fold Replies
- Healthywealt:
  Sure
  2021-04-19
  Reply
  Report
张家二少爷
·2021-04-18
Oh no
Reply
2
Report
Fold Replies
- hellojo:
  Oh no
  2021-04-20
  Reply
  Report
- hellojo:
  Ih no
  2021-04-19
  Reply
  Report
stormlee
·2021-04-18
Comment & like pls
Reply
2
Report
Fold Replies
- Healthywealt:
  Sure
  2021-04-19
  Reply
  Report
Hammer6895
·2021-04-18
Good read.
Reply
2
Report
Fold Replies
- Acestars:
  lol
  2021-04-18
  Reply
  Report
- dandan_4896:
  i love u bb
  2021-04-18
  Reply
  Report
- Hammer6895:
  Who are you? ?
  2021-04-18
  Reply
  Report
MarcO
·2021-04-18
What happened
Reply
Like
Report
Fold Replies
- Lawsford:
  ? who are u
  2021-04-19
  Reply
  Report
- dandan_4896:
  i love u bb
  2021-04-18
  Reply
  Report
Rocket2ocean
·2021-04-18
Good
Reply
1
Report
Fold Replies
- Jovvvvv:
  ??
  2021-04-18
  Reply
  Report
JaNice
·2021-04-18
Yea
Reply
1
Report
Fold Replies
- Rocket2ocean:
  Good
  2021-04-18
  Reply
  Report
Ironteam
·2021-04-18
This company will do well in the long term. Buy it while on offer!
Reply
1
Report
Fold Replies
- Lawsford:
  elaborate?
  2021-04-19
  Reply
  Report
- Isaacs:
  Agree
  2021-04-18
  Reply
  Report
mimiyo
·2021-04-18
Yes
Reply
Like
Report
Fold Replies
- Stormytw:
  crispr
  2021-04-18
  Reply
  Report
AntonyGeorge
·2021-04-18
Rip
Reply
1
Report
albert77
·2021-04-18
Oh no
Reply
Like
Report
Zhengheng123
·2021-04-18
any idea when it’ll go up?
Reply
1
Report
Boo2bear
·2021-04-18
Too many retailers in penny Stocks, causes volatily
Reply
1
Report
janelie
·2021-04-18
Time to buy?
Reply
1
Report
Dittosg
·2021-04-18
Just taking profits
Reply
2
Report
Fold Replies
- 心投资:
  Good
  2021-04-19
  Reply
  Report
LohYK
·2021-04-18
No reason ..simply just selldown.
Reply
Like
Report
TC88
·2021-04-18
Terrible
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2127485530?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-04-16 23:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2127485530","market":"us","top_or_hot":-1,"title":"Why Bionano Genomics Stock Is Tumbling Today","media":"Motley Fool","content":"<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","article_id":"2127485530","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","pubTimestamp":1618585200,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"No news; just run-of-the-mill volatility.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics"},"translate_title":"为什么Bionano Genomics股价今天暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":0.9},"content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":375322408,"gmtCreate":1619310903404,"gmtModify":1704722213422,"author":{"id":"3577083545878274","authorId":"3577083545878274","name":"Plutosg","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"I was worried for a while when the stock avalanched the last week.&nbsp;","listText":"I was worried for a while when the stock avalanched the last week.&nbsp;","text":"I was worried for a while when the stock avalanched the last week.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375322408","repostId":2127485530,"repostType":2,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":371841629,"gmtCreate":1618928414561,"gmtModify":1704717064934,"author":{"id":"3578172115401354","authorId":"3578172115401354","name":"VikiSoh","avatar":"https://static.tigerbbs.com/2130cfe283666b13556b33ac1d8d56e0","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Bionano is best left to aggressive investors. And for these investors, Bionano is a great stock to buy in April.","listText":"Bionano is best left to aggressive investors. And for these investors, Bionano is a great stock to buy in April.","text":"Bionano is best left to aggressive investors. And for these investors, Bionano is a great stock to buy in April.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/371841629","repostId":2127485530,"repostType":2,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":371964464,"gmtCreate":1618903541558,"gmtModify":1704716621263,"author":{"id":"3577103672190304","authorId":"3577103672190304","name":"ziqii","avatar":"https://static.tigerbbs.com/292e38661a1a4712ada006c4ee6b3400","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"shag sia","listText":"shag sia","text":"shag sia","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/371964464","repostId":2127485530,"repostType":2,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5182664,"gmtCreate":1625932587531,"gmtModify":1663230803446,"authorId":3577103672190304,"author":{"id":3577103672190304,"authorId":3577103672190304,"name":"ziqii","avatar":"https://static.tigerbbs.com/292e38661a1a4712ada006c4ee6b3400","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":371964464,"type":1,"supId":0,"prevId":0,"content":"hais","text":"hais","html":"hais"}],"langContent":"EN"},{"id":379430799,"gmtCreate":1618788534911,"gmtModify":1704714770705,"author":{"id":"3567411499210880","authorId":"3567411499210880","name":"Nebhol","avatar":"https://static.tigerbbs.com/b0bfc2a45b91e41a283614268857b3a5","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Comment and like please","listText":"Comment and like please","text":"Comment and like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/379430799","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4068724,"gmtCreate":1618790755051,"gmtModify":1680784584014,"authorId":3570225050694937,"author":{"id":3570225050694937,"authorId":3570225050694937,"name":"Healthywealt","avatar":"https://static.tigerbbs.com/802d7bb7b00616d6cb259efbcaeef7a5","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379430799,"type":1,"supId":0,"prevId":0,"content":"Sure","text":"Sure","html":"Sure"}],"langContent":"EN"},{"id":379519190,"gmtCreate":1618760447410,"gmtModify":1704714653654,"author":{"id":"3578640057424295","authorId":"3578640057424295","name":"张家二少爷","avatar":"https://community-static.tradeup.com/news/7a12bca4ab5f122bdf3f13efcca1ec27","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":6,"crmLevelSwitch":1},"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/379519190","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4080356,"gmtCreate":1618889864301,"gmtModify":1680784767353,"authorId":3579348570026993,"author":{"id":3579348570026993,"authorId":3579348570026993,"name":"hellojo","avatar":"https://static.tigerbbs.com/a01d3a5321c3e239c9873e21529537e7","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.66%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379519190,"type":1,"supId":0,"prevId":0,"content":"Oh <u>no</u>","text":"Oh <u>no</u>","html":"Oh <u>no</u>"},{"id":4075664,"gmtCreate":1618844474371,"gmtModify":1680784682632,"authorId":3579348570026993,"author":{"id":3579348570026993,"authorId":3579348570026993,"name":"hellojo","avatar":"https://static.tigerbbs.com/a01d3a5321c3e239c9873e21529537e7","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.66%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379519190,"type":1,"supId":0,"prevId":0,"content":"Ih <u>no</u>","text":"Ih <u>no</u>","html":"Ih <u>no</u>"}],"langContent":"EN"},{"id":379533411,"gmtCreate":1618758926333,"gmtModify":1704714642297,"author":{"id":"3571959390768435","authorId":"3571959390768435","name":"stormlee","avatar":"https://static.tigerbbs.com/80629ef9648273c0d6465aee66dbd98a","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Comment &amp; like pls","listText":"Comment &amp; like pls","text":"Comment & like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/379533411","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4068728,"gmtCreate":1618790764503,"gmtModify":1680784584370,"authorId":3570225050694937,"author":{"id":3570225050694937,"authorId":3570225050694937,"name":"Healthywealt","avatar":"https://static.tigerbbs.com/802d7bb7b00616d6cb259efbcaeef7a5","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379533411,"type":1,"supId":0,"prevId":0,"content":"Sure","text":"Sure","html":"Sure"}],"langContent":"EN"},{"id":379257967,"gmtCreate":1618751832859,"gmtModify":1704714582667,"author":{"id":"3581728634208255","authorId":"3581728634208255","name":"Hammer6895","avatar":"https://static.tigerbbs.com/2fbf05ea7876e002419f6f7b219d64fb","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Good read.&nbsp;","listText":"Good read.&nbsp;","text":"Good read.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/379257967","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4067197,"gmtCreate":1618759543009,"gmtModify":1680784555260,"authorId":3571037900661236,"author":{"id":3571037900661236,"authorId":3571037900661236,"name":"Acestars","avatar":"https://static.tigerbbs.com/cb536be016acf6e75b6c4b057fc2395b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379257967,"type":1,"supId":0,"prevId":0,"content":"lol","text":"lol","html":"lol"},{"id":4066739,"gmtCreate":1618752746491,"gmtModify":1680784551295,"authorId":3576232257279797,"author":{"id":3576232257279797,"authorId":3576232257279797,"name":"dandan_4896","avatar":"https://static.tigerbbs.com/d8b00e27a4dd6f248e38c3d78f21f188","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379257967,"type":1,"supId":0,"prevId":0,"content":"i love u bb","text":"i love u bb","html":"i love u bb"},{"id":4066754,"gmtCreate":1618752878658,"gmtModify":1680784545275,"authorId":3581728634208255,"author":{"id":3581728634208255,"authorId":3581728634208255,"name":"Hammer6895","avatar":"https://static.tigerbbs.com/2fbf05ea7876e002419f6f7b219d64fb","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379257967,"type":1,"supId":0,"prevId":0,"content":"Who are you? ?","text":"Who are you? ?","html":"Who are you? ?"}],"langContent":"EN"},{"id":379258073,"gmtCreate":1618750948192,"gmtModify":1704714575877,"author":{"id":"3579404034455974","authorId":"3579404034455974","name":"MarcO","avatar":"https://static.tigerbbs.com/be5697566d0f1acd47a2c200cbfe60f0","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"What happened&nbsp;","listText":"What happened&nbsp;","text":"What happened","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/379258073","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4067382,"gmtCreate":1618763036864,"gmtModify":1680784553612,"authorId":3581808238091509,"author":{"id":3581808238091509,"authorId":3581808238091509,"name":"Lawsford","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379258073,"type":1,"supId":4066740,"prevId":0,"content":"? who are <u>u</u>","text":"? who are <u>u</u>","html":"? who are <u>u</u>"},{"id":4066740,"gmtCreate":1618752752638,"gmtModify":1680784548026,"authorId":3576232257279797,"author":{"id":3576232257279797,"authorId":3576232257279797,"name":"dandan_4896","avatar":"https://static.tigerbbs.com/d8b00e27a4dd6f248e38c3d78f21f188","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379258073,"type":1,"supId":0,"prevId":0,"content":"i love u bb","text":"i love u bb","html":"i love u bb"}],"langContent":"EN"},{"id":379267402,"gmtCreate":1618748824706,"gmtModify":1704714555612,"author":{"id":"3573564985836603","authorId":"3573564985836603","name":"Rocket2ocean","avatar":"https://static.tigerbbs.com/871ff8b7f4e7fb157bec1151aefa3930","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/379267402","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4066660,"gmtCreate":1618751839661,"gmtModify":1680784549265,"authorId":3575115093974562,"author":{"id":3575115093974562,"authorId":3575115093974562,"name":"Jovvvvv","avatar":"https://static.tigerbbs.com/0ad373080935330fb3711b001e92b5fd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379267402,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"}],"langContent":"EN"},{"id":379267853,"gmtCreate":1618748711872,"gmtModify":1704714555093,"author":{"id":"3574939383328580","authorId":"3574939383328580","name":"JaNice","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Yea","listText":"Yea","text":"Yea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/379267853","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4066485,"gmtCreate":1618748855323,"gmtModify":1680784540328,"authorId":3573564985836603,"author":{"id":3573564985836603,"authorId":3573564985836603,"name":"Rocket2ocean","avatar":"https://static.tigerbbs.com/871ff8b7f4e7fb157bec1151aefa3930","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379267853,"type":1,"supId":0,"prevId":0,"content":"Good","text":"Good","html":"Good"}],"langContent":"EN"},{"id":379281137,"gmtCreate":1618745722929,"gmtModify":1704714533729,"author":{"id":"3561582804451218","authorId":"3561582804451218","name":"Ironteam","avatar":"https://static.tigerbbs.com/820ff4e88bef87bdd250ce62ad08f334","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":5,"crmLevelSwitch":1},"htmlText":"This company will do well in the long term. Buy it while on offer!","listText":"This company will do well in the long term. Buy it while on offer!","text":"This company will do well in the long term. Buy it while on offer!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/379281137","repostId":2127485530,"repostType":2,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4067384,"gmtCreate":1618763052577,"gmtModify":1680784556030,"authorId":3581808238091509,"author":{"id":3581808238091509,"authorId":3581808238091509,"name":"Lawsford","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379281137,"type":1,"supId":4066331,"prevId":0,"content":"elaborate?","text":"elaborate?","html":"elaborate?"},{"id":4066331,"gmtCreate":1618746702377,"gmtModify":1680784539791,"authorId":3579691414589442,"author":{"id":3579691414589442,"authorId":3579691414589442,"name":"Isaacs","avatar":"https://static.tigerbbs.com/112470e447f8d8299a741b4aafca65d8","vip":1,"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379281137,"type":1,"supId":0,"prevId":0,"content":"Agree","text":"Agree","html":"Agree"}],"langContent":"EN"},{"id":379213355,"gmtCreate":1618743547977,"gmtModify":1704714519098,"author":{"id":"3577269694288591","authorId":"3577269694288591","name":"mimiyo","avatar":"https://static.tigerbbs.com/6810fe2df9a878f5d8704b4bf84cffbb","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/379213355","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4066382,"gmtCreate":1618747336768,"gmtModify":1680784543529,"authorId":3564008227112773,"author":{"id":3564008227112773,"authorId":3564008227112773,"name":"Stormytw","avatar":"https://static.tigerbbs.com/e52e3d83a9b8426eb631c8696b5c6197","vip":2,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.26","exceedPercentage":"80.05%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379213355,"type":1,"supId":0,"prevId":0,"content":"crispr","text":"crispr","html":"crispr"}],"langContent":"EN"},{"id":379235047,"gmtCreate":1618742583289,"gmtModify":1704714512420,"author":{"id":"3575960528012254","authorId":"3575960528012254","name":"AntonyGeorge","avatar":"https://static.tigerbbs.com/42c9567b5a3657003840b0dc4fcee15c","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Rip","listText":"Rip","text":"Rip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379235047","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":379294781,"gmtCreate":1618740541143,"gmtModify":1704714500776,"author":{"id":"3575421087208890","authorId":"3575421087208890","name":"albert77","avatar":"https://static.tigerbbs.com/23ad8bf74e09800b779350089d72b84f","vip":1,"crmLevel":2,"crmLevelSwitch":1},"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379294781","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":379206213,"gmtCreate":1618737693832,"gmtModify":1704714481878,"author":{"id":"3575172203718786","authorId":"3575172203718786","name":"Zhengheng123","avatar":"https://static.tigerbbs.com/207ef86b32ebf7faaa1d899f571b3d2a","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"any idea when it’ll go up?","listText":"any idea when it’ll go up?","text":"any idea when it’ll go up?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379206213","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":379200591,"gmtCreate":1618736756813,"gmtModify":1704714475101,"author":{"id":"3578969648963961","authorId":"3578969648963961","name":"Boo2bear","avatar":"https://static.tigerbbs.com/209ae746c8124fe2d5f79aee784d2fcc","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Too many retailers in penny Stocks, causes volatily","listText":"Too many retailers in penny Stocks, causes volatily","text":"Too many retailers in penny Stocks, causes volatily","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379200591","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":379673251,"gmtCreate":1618735366573,"gmtModify":1704714464577,"author":{"id":"3579574135370824","authorId":"3579574135370824","name":"janelie","avatar":"https://static.tigerbbs.com/f929201b4c664d977cd55eb2e9c16841","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":3,"crmLevelSwitch":0},"htmlText":"Time to buy?","listText":"Time to buy?","text":"Time to buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379673251","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":379644907,"gmtCreate":1618734820609,"gmtModify":1704714458828,"author":{"id":"3576934932610535","authorId":"3576934932610535","name":"Dittosg","avatar":"https://static.tigerbbs.com/1b2cff59f82218916755d7d3ff0253b2","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Just taking profits&nbsp;","listText":"Just taking profits&nbsp;","text":"Just taking profits","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/379644907","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4067751,"gmtCreate":1618784036560,"gmtModify":1680784563659,"authorId":3578738582837184,"author":{"id":3578738582837184,"authorId":3578738582837184,"name":"心投资","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":379644907,"type":1,"supId":0,"prevId":0,"content":"Good","text":"Good","html":"Good"}],"langContent":"EN"},{"id":379641418,"gmtCreate":1618733990534,"gmtModify":1704714452544,"author":{"id":"3568070265339857","authorId":"3568070265339857","name":"LohYK","avatar":"https://static.tigerbbs.com/d6add0343094f5e965e831fa432314ef","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":8,"crmLevelSwitch":1},"htmlText":"No reason ..simply just selldown.&nbsp;","listText":"No reason ..simply just selldown.&nbsp;","text":"No reason ..simply just selldown.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379641418","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":379657051,"gmtCreate":1618733351773,"gmtModify":1704714446620,"author":{"id":"3569493945217915","authorId":"3569493945217915","name":"TC88","avatar":"https://static.tigerbbs.com/ea49250ec06f06d5c0a8d65dbd1900ef","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Terrible","listText":"Terrible","text":"Terrible","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379657051","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","pubTimestamp":1618585200,"share":"https://www.laohu8.com/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":311,"commentSize":95,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}